Abstract
Nitric oxide is multifunctional messenger molecule in the brain, playing important roles including in learning and memory and in regulating the expression of trophic factors that may be reduced with aging. Small molecules that mimic the biological activity of NO, NO mimetics, will bypass cholinergic receptor activation and are anticipated to provide multiple pathways of treating and circumventing dementia in Alzheimers disease. Activation of soluble guanylyl cyclase and cGMP formation in the brain represents one element of effective neuroprotective pathways mediated by NO. Substantial evidence suggests that NO mimetics may display cGMP-dependent and cGMP-independent activity and may operate via multiple biochemical signaling pathways, both to ensure the survival of neurons subjected to stress and also to provide cognition-enabling pathways to circumvent dementia. GT 1061 is an NO mimetic compound currently in clinical trials for Alzheimers. A survey of current research indicates that NO mimetics will provide a combined neuroprotective and cognition-enabling approach to anti-neurodegenerative therapy.
Keywords: cognition, dementia, nitric oxide, cgmp, nitrate, alzheimers, neurodegeneration, bdnf
Current Alzheimer Research
Title: Nitric Oxide Mimetic Molecules as Therapeutic Agents in Alzheimers Disease
Volume: 2 Issue: 2
Author(s): Gregory R.J. Thatcher, Brian M. Bennett and James N. Reynolds
Affiliation:
Keywords: cognition, dementia, nitric oxide, cgmp, nitrate, alzheimers, neurodegeneration, bdnf
Abstract: Nitric oxide is multifunctional messenger molecule in the brain, playing important roles including in learning and memory and in regulating the expression of trophic factors that may be reduced with aging. Small molecules that mimic the biological activity of NO, NO mimetics, will bypass cholinergic receptor activation and are anticipated to provide multiple pathways of treating and circumventing dementia in Alzheimers disease. Activation of soluble guanylyl cyclase and cGMP formation in the brain represents one element of effective neuroprotective pathways mediated by NO. Substantial evidence suggests that NO mimetics may display cGMP-dependent and cGMP-independent activity and may operate via multiple biochemical signaling pathways, both to ensure the survival of neurons subjected to stress and also to provide cognition-enabling pathways to circumvent dementia. GT 1061 is an NO mimetic compound currently in clinical trials for Alzheimers. A survey of current research indicates that NO mimetics will provide a combined neuroprotective and cognition-enabling approach to anti-neurodegenerative therapy.
Export Options
About this article
Cite this article as:
Thatcher R.J. Gregory, Bennett M. Brian and Reynolds N. James, Nitric Oxide Mimetic Molecules as Therapeutic Agents in Alzheimers Disease, Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585945
DOI https://dx.doi.org/10.2174/1567205053585945 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Trajectories of Age-Related Cognitive Decline and Potential Associated Factors of Cognitive Function in Senior Citizens of Beijing
Current Alzheimer Research The Role of Adipocytokines and Neurohormonal Dysregulation in Metabolic Syndrome
Current Diabetes Reviews On the Interaction of β-Amyloid Peptides and α7-Nicotinic Acetylcholine Receptors in Alzheimer’s Disease
Current Alzheimer Research Development and Validation of a Fluorescence-Based HTS Assay for the Identification of P/Q-Type Calcium Channel Blockers
Combinatorial Chemistry & High Throughput Screening Antibodies As Promising Novel Neuroprotective Agents in the Central Nervous System Injuries
Central Nervous System Agents in Medicinal Chemistry Intranasal Insulin Prevents Anesthesia-induced Cognitive Impairments in Aged Mice
Current Alzheimer Research Adenosine and Stroke: Maximizing the Therapeutic Potential of Adenosine as a Prophylactic and Acute Neuroprotectant
Current Neuropharmacology Oral Lipid Based Drug Delivery System (LBDDS): Formulation, Characterization and Application: A Review
Current Drug Delivery Meet Our Editorial Board Member
Current Neuropharmacology Synthesis and In Vitro Evaluation of New Tacrine Derivates-Bis-Alkylene Linked 7-MEOTA
Letters in Organic Chemistry Targeting Tau Hyperphosphorylation <I>via</I> Kinase Inhibition: Strategy to Address Alzheimer's Disease
Current Topics in Medicinal Chemistry Antioxidative Effects of Rhodiola Genus: Phytochemistry and Pharmacological Mechanisms against the Diseases
Current Topics in Medicinal Chemistry Preface [Hot topic: Potential Therapeutic Agents for Parkinsons Disease (Executive Editor: Masato Asanuma)]
Current Pharmaceutical Design East Meets West in the Search for Alzheimers Therapeutics - Novel Dimeric Inhibitors from Tacrine and Huperzine A
Current Alzheimer Research Chondromodulin-I and Tenomodulin: The Negative Control of Angiogenesis in Connective Tissue
Current Pharmaceutical Design Newly Diagnosed Dementia and Increased Risk of Hemorrhagic Stroke: A Nationwide Population-based Study
Current Alzheimer Research Assessing Activation States in Microglia
CNS & Neurological Disorders - Drug Targets Dietary Omega 3 Polyunsaturated Fatty Acids and Alzheimers Disease: Interaction with Apolipoprotein E Genotype
Current Alzheimer Research Health-Care Associated Pneumonia (HCAP): Identification of Low and High-Risk Patients
Current Respiratory Medicine Reviews Osteoprotegerin in Cardiovascular Disease: Ally or Enemy?
Current Pharmaceutical Design